Neural Monitoring of Acute Care Patients

The system has been cleared by the U.S. Food and Drug Administration (FDA).

The system comprises the NeuroPort cortical microelectrode array (NeuroPort array) and the NeuroPort neural signal processor (NeuroPort NSP). The NeuroPort system provides neurologists and neurosurgeons with a new resource to detect, transmit, and analyze neural activity of patients who have undergone craniotomy. The array allows the collection of aggregate or individual neural signals from the cortical region of the brain. The NSP allows these signals to be recorded and analyzed by the doctor as a part of the diagnosis and treatment of neurologic conditions.

"Marketing clearance of the NeuroPort system, our first commercial clinical product, is an important first step in our strategy to develop a broad family of products to diagnose, monitor, and treat neurological diseases and injuries,” noted Timothy R. Surgenor, president and CEO of Cyberkinetics Neurotechnology Systems, Inc. (Foxborough, MA, USA), which developed the system. "The NeuroPort array and the NeuroPort SNP are both critical components derived from our BrainGate neural interface system.”





Related Links:
Cyberkinetics